Octanine (Human Coagulation Factor Ix)

Human coagulation factor IX is a vitamin K‑dependent plasma protein that participates in the intrinsic pathway of the coagulation cascade. When administered, it binds to activated factor VIII, forming a complex that converts factor X to Xa, leading to thrombin generation and fibrin clot formation, thereby restoring normal clotting function.

The dose of Octanine is individualized and determined by the prescribing healthcare professional based on the patient’s factor IX activity level, severity of deficiency, body weight, and clinical situation. The prescriber calculates the required units to achieve target plasma levels and adjusts subsequent dosing according to laboratory monitoring.

Safety data for Octanine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Treatment decisions should be made by the obstetrician and hematologist in collaboration with the patient.

To place an order, submit an enquiry on the Octanine product page at gnhindia.com, specifying the required quantity and providing institutional or trade credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, then replies with pricing, availability, shipping arrangements (including cold‑chain logistics) and any necessary import documentation.

Octanine is a human‑derived factor IX concentrate, similar in composition to other plasma‑derived or recombinant factor IX products. Compared with recombinant alternatives, Octanine may have a different immunogenic profile and may be preferred in settings where plasma‑derived products are standard. Clinical efficacy and safety are comparable when used according to guidelines.

Octanine should be stored at 2‑8 °C (refrigerated) in its original container, protected from light. Do not freeze or shake the product. If temperature excursions occur, discard the vial according to the manufacturer’s instructions to maintain product stability and potency.

Octanine is given by intravenous infusion. The healthcare professional reconstitutes the vial with the appropriate diluent, then administers the solution slowly, usually over several minutes, while monitoring the patient for any infusion‑related reactions. Dosage and infusion rate are guided by factor IX activity measurements.

The most serious risks include the development of neutralizing antibodies (inhibitors) against factor IX, which can reduce efficacy, and rare thrombotic events such as deep‑vein thrombosis or pulmonary embolism. Anaphylactic reactions and severe hypersensitivity may also occur, requiring immediate medical attention.

Octanine is contraindicated in patients with known hypersensitivity to human coagulation factor IX products or any excipients in the formulation. It should also be avoided in individuals with a history of severe inhibitor development unless under specialist supervision. Use in patients with uncontrolled thrombosis risk should be carefully evaluated.